Introduction
Use of combinations of antifungal drugs not only reduces the chance of emergence of drug resistance but may also increase the effectiveness by acting together either synergically or additively. 1, 2 Although there are several classes of conventional (e.g. polyenes and azoles) and investigational (e.g. echinocandins, nikkomycins, sordarins, morpholines and allylamines) antifungal agents available now, very little is known about the activity of combinations of these antifungal agents against pathogenic filamentous fungi. Voriconazole exhibits excellent in vitro and in vivo activity against a wide spectrum of fungi, including Aspergillus species. 3, 4 On the other hand, the echinocandin caspofungin shows inhibitory effects on the growth of Aspergillus fumigatus at low concentrations 5 with very little killing of the A. fumigatus cells even after prolonged exposure to the drug. Since the echinocandins and the triazoles are different classes of antifungal drugs with distinct modes of action, two-drug combination of an azole with an echinocandin may provide synergic interaction against susceptible microorganisms. We therefore investigated the in vitro susceptibility of 20 clinical isolates of A. fumigatus to four triazoles alone and in two-drug combinations with caspofungin using the fractional inhibitory concentration index method. 6 
Materials and methods

Antifungal drugs
Voriconazole, itraconazole, posaconazole and ravuconazole were obtained from Pfizer Pharmaceuticals (New York, NY, USA), Janssen Pharmaceutica (Beerse, Belgium), ScheringPlough Research Institute (Kenilsworth, NJ, USA) and Bristol-Myers Squibb Institute for Medical Research (Princeton, NJ, USA), whereas caspofungin was obtained from Merck and Company (Rahway, NJ, USA), respectively. The triazoles were dissolved in dimethyl sulphoxide to obtain a stock solution of 1 g/L and stored as 0.25 mL lots at -20°C. Caspofungin was dissolved in sterile double-distilled water to obtain a concentration of 10 g/L and stored as 0.25 mL lots at -70°C. The frozen stocks of the antifungal agents were thawed at room temperature and used within 24 h.
Determination of fractional inhibitory concentration index (FICI)
Twenty clinical isolates of A. fumigatus obtained from the Microbiology Laboratory of the Detroit Medical Center (Detroit, MI, USA) were used in this study. Conidial suspensions from 7-day-old A. fumigatus cultures were prepared, standardized by haemocytometry and used as inoculum for susceptibility testing. The in vitro susceptibility of A. fumigatus to two-drug combinations of caspofungin with various triazoles was evaluated by the FICI method determined by two-dimensional chequerboard using the National Committee for Clinical and Laboratory Standards M38-A broth microdilution technique. 7 This is the reference method for testing filamentous fungi with azoles, amphotericin B and flucytosine, and has not yet been validated for caspofungin. Pair-wise combinations of the required concentrations of caspofungin (antifungal A) and the required triazole (antifungal B) were prepared in two-fold increments in 0.1 mL RPMI 1640 containing 0.165 M MOPS buffer (pH 7.0). Eleven wells in the top row and seven wells in the first column contained various concentrations of caspofungin and the triazole alone, respectively. The well at the top left corner of the microdilution plate contained no drug (drug-free growth control). The other 77 wells in the microdilution plate contained combinations of various concentrations of caspofungin and the required triazole. To each well, 0.1 mL of fresh conidial suspension (2 × 10 4 conidia/mL) was added. The content of each well of the microdilution plate was mixed by repeated pipetting back and forth with a multichannel pipette. The plate was incubated at 35°C for 48 h and the MIC-0 was defined as the concentration of the drug that provided no visible growth as determined by the reduction of the tetrazolium compound 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) by the fungal cells. 8 The microdilution plate well that represents the lowest concentration(s) of the drug(s) with no visible colour was taken as the end-point. Drug concentrations with a range of either 0.015-1 mg/L (triazoles) or 0.062-64 mg/L (caspofungin) were used for MIC determinations. 
Results and discussion
We used 20 clinical isolates of A. fumigatus randomly selected from our collection (n = 619) obtained from the Detroit Medical Center (Detroit, MI, USA). All 20 isolates were highly susceptible to itraconazole (MIC-0 Table 1 . Both itraconazole and its analogue posaconazole showed synergic in vitro interaction whereas voriconazole and its analogue ravuconazole showed no interaction. We found no evidence of antagonism for the azole plus echinocandin combination.
The primary fungal target of action for all azoles, including triazoles, is believed to be the cytochrome P450-dependent lanosterol 14α-demethylase, an enzyme essential for the synthesis of ergosterol. 9, 10 The differential interaction of triazoles with caspofungin (inhibitor of cell wall synthesis by interfering with the function of glucan synthase) could not have been predicted based on the modes of action of these two classes of antifungal drugs. The fact that these two classes The reason(s) for the differential in vitro activity of triazoles in two-drug combinations with caspofungin is at present only a matter of speculation. However, it is possible that the effect occurs only in vitro and has no in vivo correlation. The azoles may have additional less prominent mode(s) of action and such a minor mode of action is enhanced prominently in combination with caspofungin in the case of certain triazoles resulting in increased efficacy. Moreover, it is possible that the uptake of azoles is selectively interfered with or enhanced in the presence of caspofungin. Alternatively, it is possible that differential lipophilicity of the four triazoles may play a role in their differential interaction in combination with caspofungin. Itraconazole and posaconazole with their long hydrophobic aliphatic tail region will be more lipid soluble than voriconazole and ravuconazole. The lipophilic itraconazole and posaconazole interact synergically with caspofungin, a cyclic lipohexapeptide compound, whereas voriconazole and ravuconazole are unable to do so. These results indicate that the in vitro interactions of members from two drug classes are not always identical and hence are not predictable.
